Literature DB >> 29375121

Guillain-Barré syndrome, transverse myelitis and infectious diseases.

Yhojan Rodríguez1, Manuel Rojas1, Yovana Pacheco1, Yeny Acosta-Ampudia1, Carolina Ramírez-Santana1, Diana M Monsalve1, M Eric Gershwin2, Juan-Manuel Anaya3.   

Abstract

Guillain-Barré syndrome (GBS) and transverse myelitis (TM) both represent immunologically mediated polyneuropathies of major clinical importance. Both are thought to have a genetic predisposition, but as of yet no specific genetic risk loci have been clearly defined. Both are considered autoimmune, but again the etiologies remain enigmatic. Both may be induced via molecular mimicry, particularly from infectious agents and vaccines, but clearly host factor and co-founding host responses will modulate disease susceptibility and natural history. GBS is an acute inflammatory immune-mediated polyradiculoneuropathy characterized by tingling, progressive weakness, autonomic dysfunction, and pain. Immune injury specifically takes place at the myelin sheath and related Schwann-cell components in acute inflammatory demyelinating polyneuropathy, whereas in acute motor axonal neuropathy membranes on the nerve axon (the axolemma) are the primary target for immune-related injury. Outbreaks of GBS have been reported, most frequently related to Campylobacter jejuni infection, however, other agents such as Zika Virus have been strongly associated. Patients with GBS related to infections frequently produce antibodies against human peripheral nerve gangliosides. In contrast, TM is an inflammatory disorder characterized by acute or subacute motor, sensory, and autonomic spinal cord dysfunction. There is interruption of ascending and descending neuroanatomical pathways on the transverse plane of the spinal cord similar to GBS. It has been suggested to be triggered by infectious agents and molecular mimicry. In this review, we will focus on the putative role of infectious agents as triggering factors of GBS and TM.

Entities:  

Mesh:

Year:  2018        PMID: 29375121      PMCID: PMC6079071          DOI: 10.1038/cmi.2017.142

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  204 in total

1.  Differential distribution of HLA-DQ beta/DR beta epitopes in the two forms of Guillain-Barré syndrome, acute motor axonal neuropathy and acute inflammatory demyelinating polyneuropathy (AIDP): identification of DQ beta epitopes associated with susceptibility to and protection from AIDP.

Authors:  Eleni E Magira; Miltiadis Papaioakim; Irving Nachamkin; Arthur K Asbury; Chun Y Li; Tony W Ho; John W Griffin; Guy M McKhann; Dimitri S Monos
Journal:  J Immunol       Date:  2003-03-15       Impact factor: 5.422

2.  Memory B cells in Guillain-Barré syndrome.

Authors:  Qian Wang; Chunye Xing; Yanlei Hao; Qiguang Shi; Ziyou Qi; Zhanyun Lv; Yan Song; Peng Xu; Xungang Feng; Lili Zhang; Yong Zhang; Yuzhong Wang; Nobuhiro Yuki
Journal:  J Neuroimmunol       Date:  2017-01-13       Impact factor: 3.478

3.  Severe neurological complications in association with Epstein-Barr virus infection.

Authors:  E P Corssmit; M A Leverstein-van Hall; P Portegies; P Bakker
Journal:  J Neurovirol       Date:  1997-12       Impact factor: 2.643

Review 4.  Diagnosis and management of acute myelopathies.

Authors:  Adam I Kaplin; Chitra Krishnan; Deepa M Deshpande; Carlos A Pardo; Douglas A Kerr
Journal:  Neurologist       Date:  2005-01       Impact factor: 1.398

5.  SOCS3 targets Siglec 7 for proteasomal degradation and blocks Siglec 7-mediated responses.

Authors:  Selinda J Orr; Nuala M Morgan; Richard J Buick; Caroline R Boyd; Joanne Elliott; James F Burrows; Caroline A Jefferies; Paul R Crocker; James A Johnston
Journal:  J Biol Chem       Date:  2006-11-30       Impact factor: 5.157

6.  Different superantigens interact with distinct sites in the Vbeta domain of a single T cell receptor.

Authors:  S C Hong; G Waterbury; C A Janeway
Journal:  J Exp Med       Date:  1996-04-01       Impact factor: 14.307

7.  Cross-reactive anti-galactocerebroside antibodies and Mycoplasma pneumoniae infections in Guillain-Barré syndrome.

Authors:  C W Ang; A P Tio-Gillen; J Groen; P Herbrink; B C Jacobs; R Van Koningsveld; A D M E Osterhaus; F G A Van der Meché; P A van Doorn
Journal:  J Neuroimmunol       Date:  2002-09       Impact factor: 3.478

8.  Sural nerve biopsies in Guillain-Barre syndrome: axonal degeneration and macrophage-associated demyelination and absence of cytomegalovirus genome.

Authors:  R Hughes; P Atkinson; P Coates; S Hall; S Leibowitz
Journal:  Muscle Nerve       Date:  1992-05       Impact factor: 3.217

9.  The Interferon-Stimulated Gene Ifitm3 Restricts West Nile Virus Infection and Pathogenesis.

Authors:  Matthew J Gorman; Subhajit Poddar; Michael Farzan; Michael S Diamond
Journal:  J Virol       Date:  2016-08-26       Impact factor: 5.103

10.  Zika Virus Targets Human STAT2 to Inhibit Type I Interferon Signaling.

Authors:  Alesha Grant; Sanket S Ponia; Shashank Tripathi; Vinod Balasubramaniam; Lisa Miorin; Marion Sourisseau; Megan C Schwarz; Mari Paz Sánchez-Seco; Matthew J Evans; Sonja M Best; Adolfo García-Sastre
Journal:  Cell Host Microbe       Date:  2016-05-19       Impact factor: 21.023

View more
  26 in total

1.  The long and latent road to autoimmunity.

Authors:  Carlo Selmi; M Eric Gershwin
Journal:  Cell Mol Immunol       Date:  2018-03-22       Impact factor: 11.530

2.  Zika virus infection and autonomic symptoms.

Authors:  Beuy Joob; Viroj Wiwanitkit
Journal:  Clin Auton Res       Date:  2018-03-12       Impact factor: 4.435

3.  Transcriptomes in rat sciatic nerves at different stages of experimental autoimmune neuritis determined by RNA sequencing.

Authors:  Y Xue; P Yin; G Li; D Zhong
Journal:  Clin Exp Immunol       Date:  2019-08-14       Impact factor: 4.330

Review 4.  Zika virus vaccines: immune response, current status, and future challenges.

Authors:  Justin M Richner; Michael S Diamond
Journal:  Curr Opin Immunol       Date:  2018-05-10       Impact factor: 7.486

5.  Young woman with Guillain-Barré syndrome and cervical transverse myelitis-A new GBS variant, not coincidence.

Authors:  Jenna Gharzeddine; Brian Renner; Natalie Wassall; Kristen Tran; Antonio Liu
Journal:  Clin Case Rep       Date:  2020-04-21

Review 6.  Autoinflammatory and autoimmune conditions at the crossroad of COVID-19.

Authors:  Yhojan Rodríguez; Lucia Novelli; Manuel Rojas; Maria De Santis; Yeny Acosta-Ampudia; Diana M Monsalve; Carolina Ramírez-Santana; Antonio Costanzo; William M Ridgway; Aftab A Ansari; M Eric Gershwin; Carlo Selmi; Juan-Manuel Anaya
Journal:  J Autoimmun       Date:  2020-06-16       Impact factor: 7.094

7.  SARS-CoV-2 Infection Leads to Neurological Dysfunction.

Authors:  Arpan Acharya; Bhavesh D Kevadiya; Howard E Gendelman; Siddappa N Byrareddy
Journal:  J Neuroimmune Pharmacol       Date:  2020-05-23       Impact factor: 4.147

Review 8.  SARS-CoV-2 Infection and Guillain-Barré Syndrome: A Review on Potential Pathogenic Mechanisms.

Authors:  Shahrzad Shoraka; Maria Lucia Brito Ferreira; Seyed Reza Mohebbi; Amir Ghaemi
Journal:  Front Immunol       Date:  2021-05-10       Impact factor: 7.561

Review 9.  Autoimmune Neurological Conditions Associated With Zika Virus Infection.

Authors:  Yeny Acosta-Ampudia; Diana M Monsalve; Luis F Castillo-Medina; Yhojan Rodríguez; Yovana Pacheco; Susan Halstead; Hugh J Willison; Juan-Manuel Anaya; Carolina Ramírez-Santana
Journal:  Front Mol Neurosci       Date:  2018-04-11       Impact factor: 5.639

Review 10.  Guillain-Barré Syndrome as a Neurological Complication of Novel COVID-19 Infection: A Case Report and Review of the Literature.

Authors:  Sepideh Paybast; Reza Gorji; Shirin Mavandadi
Journal:  Neurologist       Date:  2020-07       Impact factor: 1.524

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.